Olema Pharmaceuticals Inc (OLMA) - Total Liabilities
Based on the latest financial reports, Olema Pharmaceuticals Inc (OLMA) has total liabilities worth $50.17 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Olema Pharmaceuticals Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how Olema Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See Olema Pharmaceuticals Inc current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Olema Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Olema Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Apotea
ST:APOTEA
|
Sweden | Skr1.28 Billion |
|
Suzhou Wanxiang Technology Co. Ltd.
SHE:301180
|
China | CN¥609.82 Million |
|
Osisko Development Corp
V:ODV
|
Canada | CA$616.83 Million |
|
Atos SE
PA:ATO
|
France | €7.27 Billion |
|
Festi hf
IC:FESTI
|
Iceland | Ikr71.24 Billion |
|
Zhejiang Baoxiniao Garment Co Ltd
SHE:002154
|
China | CN¥2.21 Billion |
|
Graincorp Ltd
AU:GNC
|
Australia | AU$1.29 Billion |
|
Kri-Kri Milk Industry S.A
AT:KRI
|
Greece | €71.78 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down Olema Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see OLMA stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Olema Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Olema Pharmaceuticals Inc (2018–2025)
The table below shows the annual total liabilities of Olema Pharmaceuticals Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $54.87 Million | +30.60% |
| 2024-12-31 | $42.02 Million | +82.28% |
| 2023-12-31 | $23.05 Million | +27.36% |
| 2022-12-31 | $18.10 Million | +59.08% |
| 2021-12-31 | $11.38 Million | +148.14% |
| 2020-12-31 | $4.58 Million | -57.25% |
| 2019-12-31 | $10.73 Million | +12.33% |
| 2018-12-31 | $9.55 Million | -- |
About Olema Pharmaceuticals Inc
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive,… Read more